Updating results

86 results

Sort: Relevance | Date

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Diagnostics guidance Published July 2019

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

Evidence-based recommendations on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Diagnostics guidance Published December 2018

Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

Evidence-based recommendations on quantitative faecal immunochemical tests (OC Sensor, HM-JACKarc and FOB Gold) to guide GP referral for colorectal cancer

Diagnostics guidance Published July 2017

High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)

Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype

Diagnostics guidance Published November 2016

Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

Evidence-based recommendations on the NIOX MINO, NIOX VERO and Nobreath devices to measure fractional exhaled nitric oxide concentration in asthma

Diagnostics guidance Published April 2014

SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for investigating diarrhoea due to bile acid malabsorption (BAM)

Diagnostics guidance Published November 2012

Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

Evidence-based recommendations on the Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M depth of anaesthesia monitors

Diagnostics guidance Published November 2012

SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

Evidence-based recommendations on theSonoVue (sulphur hexafluoride microbubbles) contrast agent for contrast-enhanced ultrasound imaging of the liver

Diagnostics guidance Published August 2012

Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting

Diagnostics guidance Published September 2014 Last updated December 2017

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

Diagnostics guidance Published May 2019

Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

Evidence-based recommendations on tests (IOTA ADNEX, Overa, RMI I, ROMA, IOTA Simple Rules) in secondary care to identify people at high risk of ovarian cancer

Diagnostics guidance Published November 2017

Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast

Diagnostics guidance Published November 2019

Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer

Diagnostics guidance Published August 2013

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)

Diagnostics guidance Published August 2013

Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

Evidence-based recommendations on viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) to detect, manage and monitor haemostasis

Diagnostics guidance Published August 2014

Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy

Diagnostics guidance Published December 2014

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Diabetic foot infection: antimicrobial prescribing

In development [GID-NG10132] Expected publication date: 11 October 2019

Antimicrobial prescribing guideline In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 10 November 2020

Antimicrobial prescribing guideline In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 26 August 2020

Diagnostics guidance In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 08 July 2020

Diagnostics guidance In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography

In development [GID-DG10034] Expected publication date: 30 September 2020

Diagnostics guidance In development

Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

In development [GID-DG10023] Expected publication date: TBC

Diagnostics guidance In development

Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Diagnostics guidance In development

KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Diagnostics guidance In development

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)

This guideline has been updated and replaced by NICE guideline NG131.

Diagnostics guidance Published June 2015

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)

Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.

Diagnostics guidance Published December 2011